Officials from Regulus Therapeutics this week said that the company continues to plan on filing two investigational new drug applications in 2014, one of which is for a microRNA-122-targeting hepatitis C treatment, but fell short of promising the goal would be met.

The comments, which were made during a conference call held to discuss Regulus' fourth-quarter financial results, contrast with those made by the executives in November, when they said they would nominate two clinical candidates before the end of 2013 and file two INDs the following year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.